Trial Profile
Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for central retinal vein occlusion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion
- Focus Therapeutic Use
- 16 Mar 2019 Status changed from active, no longer recruiting to completed.
- 20 Mar 2014 New trial record